About Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:BMY
- CUSIP: 11012210
- Web: www.bms.com
- Market Cap: $105.64 billion
- Outstanding Shares: 1,639,926,000
- 50 Day Moving Avg: $63.37
- 200 Day Moving Avg: $57.29
- 52 Week Range: $46.01 - $66.10
Sales & Book Value:
- Trailing P/E Ratio: 23.51
- Foreward P/E Ratio: 20.13
- P/E Growth: 2.10
- Annual Revenue: $20.24 billion
- Price / Sales: 5.22
- Book Value: $8.96 per share
- Price / Book: 7.19
- Annual Dividend: $1.56
- Dividend Yield: 2.4%
- EBITDA: $6.01 billion
- Net Margins: 22.66%
- Return on Equity: 32.33%
- Return on Assets: 14.86%
- Debt-to-Equity Ratio: 0.47%
- Current Ratio: 1.59%
- Quick Ratio: 1.45%
- Average Volume: 6.15 million shs.
- Beta: 1.19
- Short Ratio: 2.45
Frequently Asked Questions for Bristol-Myers Squibb Company (NYSE:BMY)
What is Bristol-Myers Squibb Company's stock symbol?
Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb Company pay dividends? What is the dividend yield for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company announced a quarterly dividend on Wednesday, September 13th. Investors of record on Friday, October 6th will be paid a dividend of $0.39 per share on Wednesday, November 1st. This represents a $1.56 annualized dividend and a dividend yield of 2.42%. The ex-dividend date is Thursday, October 5th. View Bristol-Myers Squibb Company's Dividend History.
How were Bristol-Myers Squibb Company's earnings last quarter?
Bristol-Myers Squibb Company (NYSE:BMY) announced its earnings results on Thursday, July, 27th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb Company had a net margin of 22.66% and a return on equity of 32.33%. The firm's revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company earned $0.69 EPS. View Bristol-Myers Squibb Company's Earnings History.
When will Bristol-Myers Squibb Company make its next earnings announcement?
What guidance has Bristol-Myers Squibb Company issued on next quarter's earnings?
Bristol-Myers Squibb Company updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.94.
Where is Bristol-Myers Squibb Company's stock going? Where will Bristol-Myers Squibb Company's stock price be in 2017?
17 brokerages have issued twelve-month price targets for Bristol-Myers Squibb Company's stock. Their predictions range from $49.00 to $75.00. On average, they expect Bristol-Myers Squibb Company's share price to reach $62.85 in the next twelve months. View Analyst Ratings for Bristol-Myers Squibb Company.
What are analysts saying about Bristol-Myers Squibb Company stock?
Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:
- 1. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
- 2. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
- 3. BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)
Who are some of Bristol-Myers Squibb Company's key competitors?
Some companies that are related to Bristol-Myers Squibb Company include Novartis AG (NVS), Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Celgene Corporation (CELG), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT) and Patheon NV (PTHN).
Who are Bristol-Myers Squibb Company's key executives?
Bristol-Myers Squibb Company's management team includes the folowing people:
- Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer
- Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations
- Louis S. Schmukler, President - Global Manufacturing and Supply
- Ann Powell Judge, Chief Human Resource Officer, Senior Vice President
- Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer
- Sandra Leung, Executive Vice President, General Counsel
- Murdo Gordon, Executive Vice President, Chief Commercial Officer
- Paul von Autenried, Senior Vice President, Chief Information Officer
- Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer
- Joseph C. Caldarella, Senior Vice President, Corporate Controller
Who owns Bristol-Myers Squibb Company stock?
Bristol-Myers Squibb Company's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.10%), Douglas Lane & Associates LLC (0.05%), State Treasurer State of Michigan (0.05%), Fisher Asset Management LLC (0.03%), Shell Asset Management Co. (0.03%) and Sabal Trust CO (0.03%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb Company.
Who sold Bristol-Myers Squibb Company stock? Who is selling Bristol-Myers Squibb Company stock?
Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., First Financial Bank Trust Division, State Treasurer State of Michigan, Oakbrook Investments LLC, Winslow Evans & Crocker Inc., Robeco Institutional Asset Management B.V., Quantitative Systematic Strategies LLC and Osborn Williams & Donohoe LLC. Company insiders that have sold Bristol-Myers Squibb Company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler and Sandra Leung. View Insider Buying and Selling for Bristol-Myers Squibb Company.
Who bought Bristol-Myers Squibb Company stock? Who is buying Bristol-Myers Squibb Company stock?
Bristol-Myers Squibb Company's stock was acquired by a variety of institutional investors in the last quarter, including Sabal Trust CO, Shell Asset Management Co., Douglas Lane & Associates LLC, APG Asset Management N.V., Stokes & Hubbell Capital Management LLC, Rockefeller Financial Services Inc., Mutual of America Capital Management LLC and Curbstone Financial Management Corp. View Insider Buying and Selling for Bristol-Myers Squibb Company.
How do I buy Bristol-Myers Squibb Company stock?
Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb Company's stock price today?
MarketBeat Community Rating for Bristol-Myers Squibb Company (NYSE BMY)MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $64.42.
Consensus Ratings for Bristol-Myers Squibb Company (NYSE:BMY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 8 Hold Ratings, 8 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.41)|
|Consensus Price Target: ||$62.85 (2.44% downside)|Consensus Price Target History for Bristol-Myers Squibb Company (NYSE:BMY)
Analysts' Ratings History for Bristol-Myers Squibb Company (NYSE:BMY)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/18/2017||Citigroup Inc.||Boost Price Target||Buy||$72.00||N/A|
|10/16/2017||Jefferies Group LLC||Downgrade||Buy -> Hold||$72.00||N/A|
|10/13/2017||Barclays PLC||Boost Price Target||Equal Weight||$58.00 -> $65.00||N/A|
|10/12/2017||BMO Capital Markets||Set Price Target||Sell||$49.00||N/A|
|9/19/2017||Cowen and Company||Reiterated Rating||Hold||$65.00||Low|
|9/12/2017||Hilliard Lyons||Downgrade||Long-term Buy -> Neutral||$65.00||Low|
|9/8/2017||Credit Suisse Group||Reiterated Rating||Neutral -> Hold||Low|
|9/7/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Buy||$62.00 -> $65.00||Low|
|7/28/2017||Leerink Swann||Lower Price Target||Outperform||$66.00 -> $61.00||Low|
|7/27/2017||Piper Jaffray Companies||Set Price Target||Hold||$60.00||Medium|
|7/17/2017||Deutsche Bank AG||Set Price Target||Hold||$54.00 -> $55.00||Low|
|6/26/2017||William Blair||Reiterated Rating||Outperform||Medium|
|4/25/2017||Robert W. Baird||Initiated Coverage||Outperform||Low|
|1/21/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||N/A|
|1/8/2017||Evercore ISI||Reiterated Rating||Hold||$55.00||N/A|
|10/10/2016||SunTrust Banks, Inc.||Reiterated Rating||Hold||$68.00 -> $62.00||N/A|
|8/25/2016||Morgan Stanley||Reiterated Rating||Neutral -> Hold||N/A|
|8/11/2016||Berenberg Bank||Downgrade||Buy -> Hold||$80.00 -> $70.00||N/A|
|8/11/2016||Sanford C. Bernstein||Reiterated Rating||Market Perform||$79.00 -> $65.00||N/A|
|4/6/2016||Societe Generale||Initiated Coverage||Sell||$48.00||N/A|
|12/18/2015||Atlantic Securities||Initiated Coverage||Underweight||$57.00||N/A|
|12/2/2015||Guggenheim||Upgrade||Neutral -> Buy||$82.00||N/A|
Earnings History for Bristol-Myers Squibb Company (NYSE:BMY)Earnings History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017||Q2 2017||$0.73||$0.74||$5.09 billion||$5.14 billion||View||N/A|
|4/27/2017||Q1 2017||$0.72||$0.84||$4.75 billion||$4.93 billion||View||N/A|
|1/26/2017||Q416||$0.67||$0.63||$5.14 billion||$5.24 billion||View||N/A|
|10/27/2016||Q316||$0.65||$0.77||$4.76 billion||$4.83 billion||View||Listen|
|7/28/2016||Q216||$0.67||$0.69||$4.60 billion||$4.90 billion||View||Listen|
|4/28/2016||Q116||$0.65||$0.74||$4.19 billion||$4.39 billion||View||Listen|
|1/28/2016||Q415||$0.28||$0.38||$4.07 billion||$4.29 billion||View||Listen|
|10/27/2015||Q315||$0.35||$0.39||$3.83 billion||$4.07 billion||View||Listen|
|7/23/2015||Q215||$0.36||$0.53||$3.68 billion||$4.16 billion||View||Listen|
|4/28/2015||Q115||$0.50||$0.71||$3.80 billion||$4.04 billion||View||N/A|
|1/27/2015||Q414||$0.40||$0.46||$4.02 billion||$4.26 billion||View||N/A|
|10/24/2014||Q314||$0.42||$0.45||$3.80 billion||$3.92 billion||View||Listen|
|7/24/2014||Q214||$0.44||$0.48||$3.85 billion||$3.89 billion||View||Listen|
|4/29/2014||Q114||$0.43||$0.46||$3.89 billion||$3.81 billion||View||Listen|
|1/24/2014||Q413||$0.43||$0.53||$4.30 billion||$4.44 billion||View||Listen|
|10/23/2013||Q313||$0.44||$0.46||$4.02 billion||$4.07 billion||View||Listen|
|7/25/2013||Q2 2013||$0.45||$0.44||$4.07 billion||$4.05 billion||View||Listen|
|4/25/2013||Q1 2013||$0.41||$0.41||$3.88 billion||$3.83 billion||View||Listen|
|1/24/2013||Q4 2012||$0.42||$0.47||$4.14 billion||$4.19 billion||View||Listen|
Earnings Estimates for Bristol-Myers Squibb Company (NYSE:BMY)
2017 EPS Consensus Estimate: $2.84
2018 EPS Consensus Estimate: $3.08
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Bristol-Myers Squibb Company (NYSE:BMY)
|Dividend Growth:||2.80% (3 Year Average)|
|Payout Ratio:||56.73% (Trailing 12 Months of Earnings) |
52.17% (Based on This Year's Estimates)
48.75% (Based on Next Year's Estimates)
|Track Record:||7 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Ownership Percentage: 0.23%Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Institutional Ownership Percentage: 68.84%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/6/2017||Joseph C Caldarella||SVP||Sell||9,340||$60.00||$560,400.00|| |
|8/2/2017||Theodore R Samuels II||Director||Buy||6,000||$55.94||$335,640.00|| |
|4/7/2017||Lamberto Andreotti||Director||Sell||34,000||$53.26||$1,810,840.00|| |
|3/28/2017||Lamberto Andreotti||Director||Sell||34,000||$56.17||$1,909,780.00|| |
|3/27/2017||Lamberto Andreotti||Director||Sell||17,000||$56.14||$954,380.00|| |
|3/17/2017||Louis S Schmukler||Insider||Sell||5,000||$56.49||$282,450.00|| |
|3/15/2017||Joseph C Caldarella||SVP||Sell||8,096||$57.29||$463,819.84|| |
|3/6/2017||Sandra Leung||EVP||Sell||92,405||$57.02||$5,268,933.10|| |
|2/27/2017||Theodore R Samuels II||Director||Buy||12,000||$56.77||$681,240.00|| |
|9/8/2016||Lamberto Andreotti||Director||Sell||21,600||$56.87||$1,228,392.00|| |
|8/25/2016||Lamberto Andreotti||Director||Sell||23,200||$59.17||$1,372,744.00|| |
|7/8/2016||Lamberto Andreotti||Director||Sell||23,200||$74.45||$1,727,240.00|| |
|6/28/2016||Lamberto Andreotti||Director||Sell||23,200||$72.14||$1,673,648.00|| |
|6/14/2016||John E Elicker||SVP||Sell||11,820||$72.69||$859,195.80|| |
|5/20/2016||Charles A Bancroft||CFO||Sell||30,201||$70.79||$2,137,928.79|| |
|5/16/2016||Joseph C Caldarella||SVP||Sell||3,519||$72.47||$255,021.93|| |
|5/6/2016||Sandra Leung||EVP||Sell||72,544||$70.39||$5,106,372.16|| |
|5/5/2016||Lamberto Andreotti||Director||Sell||23,200||$70.54||$1,636,528.00|| |
|5/3/2016||Giovanni Caforio||CEO||Sell||34,594||$71.31||$2,466,898.14|| |
|5/2/2016||Autenried Paul Von||SVP||Sell||37,258||$71.93||$2,679,967.94|| |
|5/2/2016||Lamberto Andreotti||Director||Sell||234,720||$71.88||$16,871,673.60|| |
|5/2/2016||Louis S Schmukler||Insider||Sell||22,218||$71.95||$1,598,585.10|| |
|4/5/2016||Lamberto Andreotti||Director||Sell||23,200||$65.90||$1,528,880.00|| |
|4/4/2016||Lamberto Andreotti||Director||Sell||11,600||$65.79||$763,164.00|| |
|3/9/2016||Lamberto Andreotti||Director||Sell||23,200||$65.71||$1,524,472.00|| |
|3/8/2016||Lewis B Campbell||Director||Sell||2,500||$66.00||$165,000.00|| |
|3/4/2016||Joseph C Caldarella||SVP||Sell||12,962||$64.64||$837,863.68|| |
|2/17/2016||Giovanni Caforio||CEO||Sell||12,040||$63.58||$765,503.20|| |
|2/17/2016||Sandra Leung||EVP||Sell||10,152||$63.57||$645,362.64|| |
|2/12/2016||Lamberto Andreotti||Director||Sell||23,200||$59.61||$1,382,952.00|| |
|1/5/2016||Lamberto Andreotti||Director||Sell||23,200||$67.56||$1,567,392.00|| |
|1/4/2016||Lamberto Andreotti||Director||Sell||11,600||$66.93||$776,388.00|| |
|12/15/2015||Lamberto Andreotti||Director||Sell||23,200||$69.03||$1,601,496.00|| |
|11/20/2015||Lamberto Andreotti||Director||Sell||23,200||$67.39||$1,563,448.00|| |
|10/6/2015||Lamberto Andreotti||Director||Sell||23,200||$60.86||$1,411,952.00|| |
|9/3/2015||Lamberto Andreotti||Director||Sell||23,200||$59.40||$1,378,080.00|| |
|6/4/2015||Joseph C Caldarella||SVP||Sell||16,972||$65.71||$1,115,230.12|| |
|3/16/2015||Francis M Cuss||EVP||Sell||114,666||$67.81||$7,775,501.46|| |
|3/16/2015||Louis S Schmukler||Insider||Sell||12,000||$66.96||$803,520.00|| |
|2/17/2015||Sandra Leung||General Counsel||Sell||11,746||$60.39||$709,340.94|| |
|2/12/2015||Samuel J Moed||SVP||Sell||3,880||$59.26||$229,928.80|| |
|2/6/2015||Samuel J Moed||SVP||Sell||21,478||$60.15||$1,291,901.70|| |
|1/29/2015||Lamberto Andreotti||CEO||Sell||90,246||$61.14||$5,517,640.44|| |
|1/29/2015||Lewis B Campbell||Director||Sell||2,500||$60.89||$152,225.00|| |
|1/29/2015||Louis S Schmukler||Insider||Sell||5,250||$60.73||$318,832.50|| |
|12/5/2014||Lamberto Andreotti||CEO||Sell||75,000||$60.31||$4,523,250.00|| |
|10/24/2014||Lamberto Andreotti||CEO||Sell||50,000||$53.00||$2,650,000.00|| |
|10/6/2014||Lamberto Andreotti||CEO||Sell||50,000||$50.99||$2,549,500.00|| |
|9/16/2014||Francis M Cuss||EVP||Sell||63,667||$50.77||$3,232,373.59|| |
|9/15/2014||Giovanni Caforio||COO||Sell||26,691||$49.87||$1,331,080.17|| |
|9/10/2014||Joseph C Caldarella||SVP||Sell||7,415||$51.03||$378,387.45|| |
|9/8/2014||Lamberto Andreotti||CEO||Sell||50,000||$51.05||$2,552,500.00|| |
|8/19/2014||Autenried Paul Von||SVP||Sell||20,000||$49.89||$997,800.00|| |
|7/29/2014||Charles A Bancroft||CFO||Sell||67,621||$51.06||$3,452,728.26|| |
|7/28/2014||Samuel J Moed||SVP||Sell||25,752||$49.32||$1,270,088.64|| |
|3/13/2014||Joseph Caldarella||SVP||Sell||9,137||$55.20||$504,362.40|| |
|3/10/2014||Lamberto Andreotti||CEO||Sell||100,000||$55.52||$5,552,000.00|| |
|3/10/2014||Louis Schmukler||Insider||Sell||8,799||$55.81||$491,072.19|| |
|3/5/2014||James Cornelius||Director||Sell||100,000||$55.82||$5,582,000.00|| |
|2/28/2014||Louis Schmukler||Insider||Sell||6,088||$54.49||$331,735.12|| |
|2/24/2014||Giovanni Caforio||EVP||Sell||41,563||$54.44||$2,262,689.72|| |
|2/19/2014||John Elicker||SVP||Sell||9,534||$54.22||$516,933.48|| |
|2/18/2014||Francis Cuss||EVP||Sell||29,800||$54.61||$1,627,378.00|| |
|2/14/2014||Charles Bancroft||CFO||Sell||52,963||$54.35||$2,878,539.05|| |
|2/14/2014||Sandra Leung||General Counsel||Sell||10,490||$54.28||$569,397.20|| |
|2/11/2014||Lamberto Andreotti||CEO||Sell||86,075||$52.66||$4,532,709.50|| |
|2/6/2014||Joseph Caldarella||SVP||Sell||35,471||$48.90||$1,734,531.90|| |
|2/5/2014||Lewis Campbell||Director||Sell||2,500||$48.28||$120,700.00|| |
|2/4/2014||James Cornelius||Director||Sell||100,000||$48.90||$4,890,000.00|| |
|7/29/2013||James M Cornelius||Director||Sell||5,000||$43.81||$219,050.00|| |
|6/10/2013||Autenried Paul Von||SVP||Sell||25,000||$47.24||$1,181,000.00|| |
|6/6/2013||Joseph C Caldarella||SVP||Sell||26,275||$46.53||$1,222,575.75|| |
|6/5/2013||John E Elicker||SVP||Sell||25,997||$46.33||$1,204,441.01|| |
|6/4/2013||Lamberto Andreotti||CEO||Sell||100,000||$47.74||$4,774,000.00|| |
|6/4/2013||Samuel J Moed||SVP||Sell||58,898||$47.38||$2,790,587.24|| |
|6/3/2013||Elliot Sigal||EVP||Sell||83,647||$48.18||$4,030,112.46|| |
|5/31/2013||Beatrice J Cazala||EVP||Sell||91,282||$47.00||$4,290,254.00|| |
|5/31/2013||Giovanni Caforio||Insider||Sell||10,538||$47.06||$495,918.28|| |
|5/30/2013||Beatrice J Cazala||EVP||Sell||22,000||$47.00||$1,034,000.00|| |
|5/28/2013||Charles A Bancroft||CFO||Sell||25,000||$48.68||$1,217,000.00|| |
|5/28/2013||James M Cornelius||Director||Sell||100,000||$47.61||$4,761,000.00|| |
|5/23/2013||Beatrice J Cazala||EVP||Sell||96,000||$46.99||$4,511,040.00|| |
|5/23/2013||Giovanni Caforio||Insider||Sell||26,647||$46.29||$1,233,489.63|| |
|5/17/2013||James M Cornelius||Director||Sell||225,996||$42.99||$9,715,568.04|| |
|5/8/2013||James M Cornelius||Director||Sell||20,000||$39.85||$797,000.00|| |
|5/2/2013||James M Cornelius||Director||Sell||20,000||$39.76||$795,200.00|| |
|4/11/2013||James M Cornelius||Director||Sell||20,000||$41.15||$823,000.00|| |
|3/13/2013||James M Cornelius||Director||Sell||20,000||$38.18||$763,600.00|| |
|3/13/2013||John E Elicker||SVP||Sell||3,409||$38.51||$131,280.59|| |
|2/27/2013||Giovanni Caforio||Insider||Sell||12,150||$37.08||$450,522.00|| |
|2/26/2013||James M Cornelius||Director||Sell||20,000||$36.58||$731,600.00|| |
|1/17/2013||James M Cornelius||Director||Sell||20,000||$34.33||$686,600.00|| |
|12/28/2012||James M Cornelius||Director||Sell||20,000||$32.06||$641,200.00|| |
|10/3/2012||James M Cornelius||Director||Sell||20,000||$33.71||$674,200.00|| |
|8/10/2012||James M Cornelius||Director||Sell||10,000||$31.81||$318,100.00|| |
Headline Trends for Bristol-Myers Squibb Company (NYSE:BMY)
Latest Headlines for Bristol-Myers Squibb Company (NYSE:BMY)
Loading headlines, please wait.
Bristol-Myers Squibb Company (BMY) Chart for Sunday, October, 22, 2017